Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ShangPharma, WuXi Buy Chinese Assets

by Jean-François Tremblay
October 31, 2011 | A version of this story appeared in Volume 89, Issue 44

The contract research firm ShangPharma is boosting its research space in China. Through its flagship subsidiary Shanghai ChemPartner, the company has bought the leases and lab equipment of Charles River Laboratories in Shanghai. The deal provides ShangPharma with about 46,000 sq ft of new space at Shanghai’s Zhangjiang Hi-Tech Park, where ChemPartner is based. Separately, WuXi PharmaTech has bought two Chinese companies performing clinical studies. MedKey Med-Tech Development and Jiecheng Med-Tech Development are related firms that employ 80 people. WuXi says the acquisitions will broaden its range of services.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.